Institutional
Paradigm Biocapital Advisors LP
CIK 0001855655
$4.89B
Reported AUM
35
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Paradigm Biocapital Advisors LP · Q1 2026
AI · grounded in 13F
Paradigm Biocapital Advisors LP closed its position in XBI for a reduction of $182.9M. The fund established new positions in INSM for $205.1M, BLTE for $177.7M, and CNTA for $142M. Additionally, the fund exited positions in CDTX and CRNX while increasing its stake in ACLXGBX by 87.35%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | ACLXGBX | ARCELLX INC | $663.0M | 13.55% | +50,000 | +0.9% |
| 2 | RVMD | REVOLUTION MEDICINES INC | $647.3M | 13.23% | +11,300 | +0.2% |
| 3 | NUVL | NUVALENT INC | $545.5M | 11.15% | +55,000 | +1.0% |
| 4 | PCVX | VAXCYTE INC | $278.5M | 5.69% | +725,000 | +17.8% |
| 5 | EWTX | EDGEWISE THERAPEUTICS INC | $232.0M | 4.74% | +823,828 | +12.6% |
| 6 | GMAB | GENMAB A/S | $213.8M | 4.37% | +928,002 | +13.2% |
| 7 | INSM | INSMED INC | $205.1M | 4.19% | +1,254,488 | NEW |
| 8 | TARS | TARSUS PHARMACEUTICALS INC | $179.7M | 3.67% | — | HELD |
| 9 | BLTE | BELITE BIO INC | $177.7M | 3.63% | +1,114,784 | NEW |
| 10 | ERAS | ERASCA INC | $168.2M | 3.44% | -3,766,393 | -26.6% |
| 11 | CNTA | CENTESSA PHARMACEUTICALS PLC | $142.0M | 2.90% | +3,574,048 | NEW |
| 12 | OLMA | OLEMA PHARMACEUTICALS INC | $119.6M | 2.44% | +476,404 | +6.3% |
| 13 | 430 | TERNS PHARMACEUTICALS INC | $116.9M | 2.39% | +1,406,213 | +173.5% |
| 14 | ORKA | ORUKA THERAPEUTICS INC | $113.8M | 2.33% | +610,000 | +35.7% |
| 15 | APGE | APOGEE THERAPEUTICS INC | $113.5M | 2.32% | +225,000 | +20.0% |
| 16 | SYRE | SPYRE THERAPEUTICS INC | $98.7M | 2.02% | +490,000 | +33.4% |
| 17 | CYTK | CYTOKINETICS INC | $97.6M | 1.99% | +1,480,857 | NEW |
| 18 | ABVX | ABIVAX SA | $86.0M | 1.76% | -645,000 | -45.5% |
| 19 | TNGX | TANGO THERAPEUTICS INC | $83.9M | 1.71% | +4,009,679 | NEW |
| 20 | MAZE | MAZE THERAPEUTICS INC | $81.9M | 1.67% | +2,744,399 | NEW |
| 21 | TYRA | TYRA BIOSCIENCES INC | $78.7M | 1.61% | +2,054,991 | NEW |
| 22 | VRDN | VIRIDIAN THERAPEUTICS INC | $61.6M | 1.26% | +1,705,791 | +118.2% |
| 23 | SRRK | SCHOLAR ROCK HLDG CORP | $60.3M | 1.23% | -1,836,077 | -60.0% |
| 24 | MIRM | MIRUM PHARMACEUTICALS INC | $57.7M | 1.18% | +625,000 | NEW |
| 25 | EYPT | EYEPOINT INC | $40.5M | 0.83% | -549,038 | -14.9% |
| 26 | LXEO | LEXEO THERAPEUTICS INC | $35.5M | 0.73% | +1,420,936 | +29.8% |
| 27 | MANE | VERADERMICS INC | $33.2M | 0.68% | +525,000 | NEW |
| 28 | VOR | VOR BIOPHARMA INC | $31.2M | 0.64% | — | HELD |
| 29 | URGN | UROGEN PHARMA LTD | $30.6M | 0.63% | -2,769,699 | -61.9% |
| 30 | GPCR | STRUCTURE THERAPEUTICS INC | $26.3M | 0.54% | +545,287 | NEW |
| 31 | IVA | INVENTIVA SA | $22.2M | 0.45% | — | HELD |
| 32 | ORIC | ORIC PHARMACEUTICALS INC | $21.6M | 0.44% | -700,000 | -29.2% |
| 33 | ASMB | ASSEMBLY BIOSCIENCES INC | $18.5M | 0.38% | — | HELD |
| 34 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $7.8M | 0.16% | -1,393,536 | -61.6% |
| 35 | KLRS | KALARIS THERAPEUTICS INC | $4.0M | 0.08% | — | HELD |
| 36 | XBI | SPDR SERIES TRUST | — | — | -1,500,000 | EXITED |
| 37 | CDTX | CIDARA THERAPEUTICS INC | — | — | -759,565 | EXITED |
| 38 | CRNX | CRINETICS PHARMACEUTICALS IN | — | — | -2,210,774 | EXITED |
| 39 | BBIO | BRIDGEBIO PHARMA INC | — | — | -684,277 | EXITED |
| 40 | OCUL | OCULAR THERAPEUTIX INC | — | — | -2,935,284 | EXITED |
Source: SEC EDGAR · accession 0001855655-26-000011. 13F discloses long positions only — shorts, foreign equities, and options are excluded.